WooGene B&G Co., Ltd. announced that it expects to receive KRW 7.526523 billion in funding from Green Cross Veterinary Products Co., Ltd.
December 15, 2019
Share
WooGene B&G Co., Ltd. (KOSDAQ:A018620) announced a private placement of 362,724 common shares at a price of KRW 20,750 per share for gross proceeds of KRW 7,526,523,000 on December 16, 2019. The shares will carry a par value of KRW 5,000 per share. The transaction will include participation from Green Cross Veterinary Products Co., Ltd. The shares will be issued through third party allotment. The transaction is expected to close on June 30, 2020. The transaction has been approved by the board of directors.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
